LAMP2

Lysosome-associated membrane glycoprotein 2 · P13473 · LAMP2 on Sugi Atlas →

0 patent compounds predicted against LAMP2, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to LAMP2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Hydroxychloroquine and Nitazoxanide Combination Therapy for COVID-19 PHASE2/PHASE3UNKNOWN
Efficacy and Safety of Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients PHASE2/PHASE3COMPLETED
Ambroxol as a Novel Disease Modifying Treatment for Lewy Body Dementia PHASE1/PHASE2NOT_YET_RECRUITING
Ambroxol as a Treatment for Parkinson's Disease Dementia PHASE2UNKNOWN
A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease PHASE2RECRUITING
High-Dose Ambroxol in GBA1-Related Parkinson PHASE1/PHASE2UNKNOWN
Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy PHASE2COMPLETED
Nilotinib in Huntington's Disease PHASE1UNKNOWN
Role of Autophagy in Type 2 Diabetes Microvascular Dysfunction EARLY_PHASE1RECRUITING
Natural History of Danon Disease nanCOMPLETED
The Natural History of Danon Disease nanUNKNOWN
Danon Disease Natural History Study nanRECRUITING
The Natural History of Alpha-Mannosidosis nanCOMPLETED
Screening of Lysosomal Storage Disorders Diseases in Minority Groups nanUNKNOWN
SRT in Comparison to ERT on Immune Aspects and Bone Involvement in Gaucher Disease nanUNKNOWN
Genetic Studies of Lysosomal Storage Disorders nanENROLLING_BY_INVITATION
Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders nanRECRUITING
Registry Gangliosidoses nanUNKNOWN
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML) nanWITHDRAWN
Establishment of Biomarkers for Fabry Disease nanCOMPLETED
Biomarker for Patients With Fabry Disease (BioFabry) nanWITHDRAWN
Endothelial Function, Inflammation and Organ Dysfunction in COVID-19 nanUNKNOWN
Evaluate the Effort Test as a Therapeutic Monitoring Tool in Acute Rhabdomyolyses nanCOMPLETED
Establishment of Human Cellular Disease Models for Wilson Disease nanCOMPLETED
Fasting, Exercise, and Diet to Activate Autophagy in Depression nanNOT_YET_RECRUITING
sCD163 in ALS Patients nanCOMPLETED
A Study to Evaluate and Characterize the Effect of Pharmacological Chemicals on Blood From Patients With Gaucher Disease nanCOMPLETED
Respiratory Cathepsins, Proteases Inhibitors and Glycosaminoglycans (GAG) in Mucopolysaccharidosis nanCOMPLETED
Autophagy Bladder Cancer nanUNKNOWN
Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a LAMP2 binder may also engage these)

ProteinNameSimilarity
P49130 1.000 P49130 →
P17047 1.000 P17047 →
Q90617 1.000 Q90617 →
P05300 1.000 P05300 →
P17046 0.998 P17046 →
Q5R5V2 0.987 Q5R5V2 →
Q9D387 0.987 Q9D387 →
A4IGL3 0.986 A4IGL3 →
A8WFR0 0.983 A8WFR0 →
A4FV27 0.980 A4FV27 →
Q9R1Q9 0.979 Q9R1Q9 →
A1L314 0.978 A1L314 →
Q5PPI4 0.978 Q5PPI4 →
Q9D7S0 0.977 Q9D7S0 →
Q9UJQ1 0.977 Q9UJQ1 →
P48829 0.976 P48829 →
Q9WV57 0.976 Q9WV57 →
Q2KJC3 0.975 Q2KJC3 →
Q6AX53 0.974 Q6AX53 →
A8WH34 0.974 A8WH34 →
O54715 0.974 O54715 →
Q6X786 0.973 Q6X786 →
Q8C186 0.973 Q8C186 →
P47984 0.973 P47984 →
P20061 0.973 P20061 →
Q6X782 0.972 Q6X782 →
Q9DC11 0.972 Q9DC11 →
A2VE33 0.972 A2VE33 →
Q7TSN7 0.972 Q7TSN7 →
Q00PJ8 0.972 Q00PJ8 →